Download biomedica product list
FGF23: A New Bone Mass Regulator in the General Population.
Fibroblast growth factor 23 (FGF23) is a protein produced by bone and is an important regulator of phosphate homeostasis. Bone impairment seen in disorders of FGF23 expression include hypophosphatemic rickets, tumoral-induced osteomalacia, and chronic kidney disease. In a study by Bilha SC et al., the researchers investigated the relationship between FGF23 and bone mass parameters in the general population, according to age, sex, menopausal, and nutritional status. FGF23 was found to be an independent predictor for bone mineral density in postmenopausal women, but was not a fine discriminator between normal bone mass and osteopenia/osteoporosis. The mechanism through which FGF23 acts upon the bone seems independent of the nutritional status, requiring further investigation. https://buff.ly/2NMb2eP
FGF23 can reliably measured by ELISA. Check out the Biomedica human FGF23 (C-terminal) and human FGF23 (intact) kits: https://buff.ly/37sunK0
• For serum and plasma samples
• Extensively validated according to international quality guidelines (FDA/ICH/EMEA)
• CE marked – for IVD use in the EU
• Plasma based standards and controls included
• Excellent correlation with existing methods